WallStSmart

Eli Lilly and Company (LLY)vsPrecision Optics Corporation, Inc. Common stock (POCI)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Eli Lilly and Company generates 266852% more annual revenue ($65.18B vs $24.42M). LLY leads profitability with a 31.7% profit margin vs -28.3%. LLY earns a higher WallStSmart Score of 78/100 (B+).

LLY

Strong Buy

78

out of 100

Grade: B+

Growth: 10.0Profit: 10.0Value: 5.0Quality: 6.5
Piotroski: 6/9Altman Z: 2.06

POCI

Avoid

32

out of 100

Grade: F

Growth: 6.7Profit: 2.0Value: 4.7Quality: 5.0
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

Intrinsic value data unavailable for LLY.

POCIFair Value (-0.4%)

Margin of Safety

-0.4%

Fair Value

$4.98

Current Price

$4.23

$0.75 premium

UndervaluedFair: $4.98Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

LLY6 strengths · Avg: 10.0/10
Market CapQuality
$760.43B10/10

Mega-cap, among the largest globally

Return on EquityProfitability
101.2%10/10

Every $100 of equity generates 101 in profit

Profit MarginProfitability
31.7%10/10

Keeps 32 of every $100 in revenue as profit

Operating MarginProfitability
44.9%10/10

Strong operational efficiency at 44.9%

Revenue GrowthGrowth
42.6%10/10

Revenue surging 42.6% year-over-year

EPS GrowthGrowth
51.4%10/10

Earnings expanding 51.4% YoY

POCI1 strengths · Avg: 10.0/10
Revenue GrowthGrowth
62.8%10/10

Revenue surging 62.8% year-over-year

Areas to Watch

LLY3 concerns · Avg: 3.0/10
P/E RatioValuation
37.0x4/10

Premium valuation, high expectations priced in

Debt/EquityHealth
1.603/10

Elevated debt levels

Price/BookValuation
31.5x2/10

Trading at 31.5x book value

POCI4 concerns · Avg: 2.8/10
EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Market CapQuality
$45.68M3/10

Smaller company, higher risk/reward

Return on EquityProfitability
-73.6%2/10

ROE of -73.6% — below average capital efficiency

Free Cash FlowQuality
$-352,4212/10

Negative free cash flow — burning cash

Comparative Analysis Report

WallStSmart Research

Bull Case : LLY

The strongest argument for LLY centers on Market Cap, Return on Equity, Profit Margin. Profitability is solid with margins at 31.7% and operating margin at 44.9%. Revenue growth of 42.6% demonstrates continued momentum.

Bull Case : POCI

The strongest argument for POCI centers on Revenue Growth. Revenue growth of 62.8% demonstrates continued momentum.

Bear Case : LLY

The primary concerns for LLY are P/E Ratio, Debt/Equity, Price/Book. Debt-to-equity of 1.60 is elevated, increasing financial risk.

Bear Case : POCI

The primary concerns for POCI are EPS Growth, Market Cap, Return on Equity.

Key Dynamics to Monitor

LLY profiles as a growth stock while POCI is a hypergrowth play — different risk/reward profiles.

LLY carries more volatility with a beta of 0.50 — expect wider price swings.

POCI is growing revenue faster at 62.8% — sustainability is the question.

LLY generates stronger free cash flow (678M), providing more financial flexibility.

Bottom Line

LLY scores higher overall (78/100 vs 32/100), backed by strong 31.7% margins and 42.6% revenue growth. Both earn "Strong Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Eli Lilly and Company

HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA

Eli Lilly and Company is an American pharmaceutical company headquartered in Indianapolis, Indiana, with offices in 18 countries. Its products are sold in approximately 125 countries.

Visit Website →

Precision Optics Corporation, Inc. Common stock

HEALTHCARE · MEDICAL INSTRUMENTS & SUPPLIES · USA

Precision Optics Corporation, Inc. designs, develops, manufactures, and sells specialized optical and lighting systems and related components primarily in the United States and the European Economic Area. The company is headquartered in Gardner, Massachusetts.

Want to dig deeper into these stocks?